TEVA PHARMACEUTICAL INDUSTRIES LTD Form 6-K March 20, 2008

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a 16 or 15d 16 under the Securities Exchange Act of 1934

For the month of March 2008

Commission File Number ______0-16174

__1__

| Teva Pharmaceutical Industries Limited |
|---|
| (Translation of registrant's name into English) |
| |
| |
| 5 Basel Street, P.O. Box 3190 |
| Petach Tikva 49131 Israel |
| |
| (Address of principal executive offices) |
| |
| |
| |
| Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F |
| |
| Form 20-F Form 40-F |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule |
| 101(b)(1): |
| |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): |
| |
| Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also hereby |
| furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934 |
| |
| Yes NoX |
| If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g(3)-2(b): |
| 82 |

| Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form 6-K | | | | |
|---|--|---|---------------------------|--|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| Teva Pharmaceutical In | ndustries Ltd. | Web Site: www.tevapharm.com | | |
| | | | | |
| | | | | |
| | | | | |
| | | | For Immediate Release | |
| | | | | |
| | | | | |
| | | thers 11th Annual Global Healthca pany 28th Annual Healthcare Conf | | |
| | | | | |
| webcast at the Lehman 28th Annual Healthcar | Brothers 11th Annual Global e Conference in Boston. Dan | reutical Industries Ltd. (Nasdaq:TEV I Healthcare Conference in Miami an Suesskind, Chief Financial Officer, Company on Wednesday, March 19. | nd at the Cowen & Company | |
| | on at the Lehman Brothers 11 28th Annual Healthcare Confe | th Annual Global Healthcare Confererence in Boston | rence in Miami and at the | |

Who: Dan Suesskind, Chief Financial Officer

When: Tuesday, March 18, 2008 @ 2:30 p.m. ET, and Wednesday, March 19, 2008 @ 8:45 a.m. ET

Where: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TEVA&item_id=1780900

or

http://cc.talkpoint.com/LEHM002/031808a jw/default.asp?entity=TevaPharmaceutical

How: Live over the Internet -- Simply log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on the site.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Western Europe.

__2__

Teva Pharmaceutical Industries Ltd. Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form 6-K Web Site: www.tevapharm.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Registrant)

By: /s/ Dan Suesskind

Name: Dan Suesskind

Title: Chief Financial Officer

Date: March 17, 2008

__3__